HeartFlow is the global leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced AI technology. Headquartered in Mountain View, California, our technology has been published in more than 500 peer-reviewed publications that showcase the value of anatomy, physiology, and plaque. We began our journey to improve coronary artery disease (CAD) diagnosis with FFRCT and have now expanded our product portfolio to include anatomic stenosis and plaque information. To date, clinicians have used our technology for over 180,000 patients to aid in the diagnosis of heart disease.
Products and Services
Coronary Computed Tomographic Angiography (CCTA) combined with selective CT-derived fractional flow reserve (FFRCT) is a non-invasive clinical pathway that helps diagnose patients with suspected CAD by using CTA images. Highly trained analysts and AI algorithms create an anatomical model of a patient’s heart that helps physicians visualize the blood flow and detect stenosis, or plaque that obstructs the blood flow.